I-Mab ADR (IMAB) Social Stream



I-Mab ADR (IMAB): $5.95

-0.19 (-3.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

I-MAB (IMAB) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering I-MAB.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-10 7 $95 $85 $90.3 $6.31 1331.06%
2022-02-09 6 $95 $85 $90.3 $6.31 1331.06%
2022-03-30 6 $95 $76 $82.133 $6.31 1201.63%
2022-05-31 7 $95 $35 $72.966 $6.31 1056.35%
2022-08-13 6 $95 $35 $72.966 $6.31 1056.35%
2022-08-30 6 $95 $35 $59.133 $6.31 837.13%
2023-01-26 6 $64.6 $25 $39.1 $6.31 519.65%

The Trend in the Analyst Price Target


IMAB's average price target has moved down $1.46 over the prior 30 months.

IMAB reports an average of 569.28% for its upside potential over the past 50 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-03-30 6 95.0 76 82.133 18.95 333.42%
2022-03-30 4 95.0 76 82.133 18.95 333.42%
2022-08-30 6 95.0 35 59.133 5.98 888.85%
2022-09-10 6 64.6 25 39.100 5.77 577.64%
2023-01-26 6 64.6 25 39.100 6.41 509.98%

IMAB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.17 5 1 0 0 0 6

The Trend in the Broker Recommendations


IMAB's average broker recommendation rating improved by 0 over the prior 122 days.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, I-MAB's upside potential (average analyst target price relative to current price) is higher than 876.92% of them.
  • IMAB has a lower variance in analysts' estimates than -292.11% of stocks in the mid market cap category.
  • IMAB has a greater average analyst price target than 715.4% of Pharmaceutical Products stocks.
  • In the context of stocks in the mid market cap category, I-MAB's number of analysts covering the stock is greater than 305.99% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to I-MAB are IGMS, KRTX, and BBIO.

Is IMAB a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6361 seconds.